MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

MRG003 (2.3 mg/kg, IV, Q3W). Treatment continues until disease progression, intolerable toxicity, withdrawal, death, or sponsor termination.

HX008 (200 mg, IV, Q3W). Treatment continues until disease progression, intolerable toxicity, withdrawal, death, or sponsor termination.